[Clinical evaluation of medicines active against trichomoniasis vaginalis in a double-blind study].
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000981:Antiprotozoal Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002181:Candidiasis, Vulvovaginal / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D003354:Corynebacterium Infections / Q000150:complications; D004927:Escherichia coli Infections / Q000150:complications; D005260:Female; D006801:Humans; D008598:Menstruation; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000150:complications; D013290:Streptococcal Infections / Q000150:complications; D013997:Time Factors; D014247:Trichomonas Vaginitis / Q000150:complications / Q000188:drug therapy*; D014246:Trichomonas vaginalis / Q000187:drug effects
D000981:Antiprotozoal Agents; D008795:Metronidazole
Klinische Auswertung aktiver Arzneimittel gegen Trichomoniasis vaginalis im Doppel-Blindversuch.